---
title: "Policy Pulse - Ministries & Regulators - 19 Oct 2026"
ticker: "SUNPHARMA:CIPLA:DRREDDY:NATCOPHARM:GLAND:EMCURE:ALKEM:ZYDUSLIFE:AJANTPHARM:MEDPLUS:APOLLOHOSP:MAXHEALTH:FORTIS:DIVISLAB:TATASTEEL:JSWSTEEL:CENTURYPLY:GREENPLY:WELSPUNLIV:TRIDENT:KPRMILL:RAJESHEXPO:POLYMED:INFY:TECHM:PERSISTENT:COFORGE:HDFCAMC:NAM-INDIA:CAMS:KFINTECH:BSE:ANGELONE:MOTILALOFS:IIFL:HDFCBANK:ICICIBANK:RELIANCE:AXISBANK:HCLTECH:WIPRO:TMPV:CDSL"
date: "2026-10-19"
tags: ["policy-pulse","pharma","pricing","fta","capital-markets"]
summary: "NPPA capped trade margins on 137 cancer drugs at 30% from November 9, a margin reset that hits MEDPLUS and re-prices oncology-heavy portfolios like NATCOPHARM, while Jio's 30x anchor book keeps BSE and ANGELONE on the right side of the primary market."
model: "deepseek-v4-flash"
---

## NPPA Caps Trade Margins on 137 Cancer Drugs at 30%, Effective November 9

The gazette notification is the most consequential Indian pricing decision since the cardiac stent and knee-implant caps. The **National Pharmaceutical Pricing Authority** has capped trade margins on **137 identified non-scheduled anti-cancer drugs** at **30% of MRP** (excluding GST), which corresponds to a mark-up of **42.86% on the price to stockist or price to distributor**.

The mechanics, from the minutes of the authority's meetings on **October 16 and 17**:

- The cap applies at the **first point of sale** — the price to a stockist, distributor or hospital when the manufacturer sells directly to them.
- The base is **March 2026 stockist prices**, so the reset is against a fixed reference rather than a live, negotiable price.
- The revised MRP is computed as **PTS/PTD × {1 + (Trade Margin / (100 - Trade Margin))} + applicable GST**.
- Manufacturers must submit revised MRPs to the pricing authority **within seven days**.
- **Revised prices take effect on November 9, 2026**, and the government estimates reductions of **up to 70%**.

The list includes patented oncology brands — **pembrolizumab, durvalumab, osimertinib, ribociclib, abemaciclib** among them. India's anti-cancer market spans roughly **225 drugs and 500 formulations with an annual turnover of around ₹12,500 crore**, so this is a narrow slice of the pharma market by value and a very concentrated one by price.

**The legal architecture is the same as the 2019 stent cap:** regulate the trade margin rather than the manufacturer's price, which is legally available for non-scheduled formulations and politically easier than bringing 137 brands into the scheduled list. It works because the gap between the price to the stockist and the MRP on these products is far wider than 42.86%.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| SUNPHARMA, CIPLA, DRREDDY, NATCOPHARM | 🟡 Watch | ⚠️ inferred. The price to the stockist is preserved by the formula, so the arithmetic is margin-neutral for the manufacturer at the point of sale. What changes is the incentive for the trade to push the brand, and that is where the volume risk sits | 2/5 |
| GLAND, EMCURE, ALKEM, ZYDUSLIFE, AJANTPHARM | 🟡 Watch | ⚠️ inferred. Injectable and oncology-heavy portfolios face the same trade-incentive reset, with the additional risk that hospital direct-supply contracts reprice first because hospitals are the named first point of sale | 2/5 |
| MEDPLUS | 🔴 Negative | ⚠️ inferred. A retail pharmacy chain earns its gross margin on exactly the spread this notification caps; oncology is a small share of footfall but among the highest ticket values per script | 2/5 |
| APOLLOHOSP, MAXHEALTH, FORTIS | 🟡 Watch | ⚠️ inferred. Hospitals buy at the regulated first point and bill at MRP, so a lower MRP cuts both their drug cost and their drug revenue; the net effect is volume and affordability, not an automatic margin gain | 2/5 |
| DIVISLAB | 🟡 Watch | ⚠️ inferred. An API and CRAMS supplier is insulated from trade margins entirely; the read-across is only through any volume response in the finished-dose oncology market | 1/5 |

## The India-New Zealand FTA Enters Into Force Tomorrow, With Zero Duty on 100% of Indian Exports

The Commerce Ministry release confirming the date is dated **September 21**, but the operative event is **October 20, 2026** — Vijay Dashmi, a date Piyush Goyal explicitly chose for its symbolism. From entry into force, **every tariff line covering 100% of India's exports to New Zealand becomes duty-free**, eliminating New Zealand's peak tariffs of up to 10%.

The material terms:

- **Gains by sector:** textiles and apparel, leather and footwear, gems and jewellery, engineering goods and processed foods enter duty-free from day one.
- **Inputs get cheaper:** Indian manufacturers get tariff-free access to **wooden logs, coking coal and metal scrap**.
- **Excluded:** dairy, animal meat (except sheep), key agricultural commodities, sugar and edible oils stay outside tariff concessions; apples, kiwifruit and Manuka honey come in through tariff-rate quotas with minimum import prices and seasonal windows.
- **Investment:** New Zealand commits to facilitate **USD 20 billion** of investment into India.
- **Services:** access across roughly **118 sectors**, MFN treatment in about **139 sub-sectors**, a dedicated quota of **5,000 Temporary Employment Entry visas** and **1,000 Working Holiday visas** a year, and uncapped student mobility.
- **Pharma and medtech:** New Zealand will accept inspection approvals from the **US FDA, EMA, UK MHRA and Health Canada**, cutting approval waiting time.
- **Scale check:** bilateral merchandise trade was about **USD 1.1 billion in 2025-26**, against an aspirational goal of **NZ$7 billion (about ₹35,000 crore)** by 2030.

That last number is the reason to keep confidence scores low. A duty-free regime on a USD 1.1 billion trade relationship is a genuine structural improvement and a rounding error against India's USD 87 billion of exports to the United States. The input duty relief is the part with real money in it.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| TATASTEEL, JSWSTEEL | 🟢 Positive | ✅ named inputs. Duty-free coking coal and metal scrap are direct input-cost relief for blast-furnace and scrap-based steelmaking, and both are price-setters on the domestic cost curve | 3/5 |
| CENTURYPLY, GREENPLY | 🟢 Positive | ✅ named inputs. Wooden logs entering duty-free is the single largest cost line for plywood and laminate manufacturers | 3/5 |
| WELSPUNLIV, TRIDENT, KPRMILL | 🟢 Positive | ✅ named sectors. Textiles and home textiles enter New Zealand duty-free from day one, removing a tariff that made Indian suppliers uncompetitive against China and Vietnam in that market | 2/5 |
| RAJESHEXPO | 🟡 Watch | ✅ named sector. Gems and jewellery is on the duty-free list, but New Zealand is a small market for Indian jewellery exports and the company's own revenue is concentrated elsewhere | 2/5 |
| SUNPHARMA, CIPLA, POLYMED | 🟢 Positive | ✅ named mechanism. Regulatory acceptance of FDA, EMA, MHRA and Health Canada inspections is a time-to-market cut, and time-to-market is the binding cost for Indian pharma and device exporters entering small developed markets | 2/5 |
| INFY, TECHM, PERSISTENT, COFORGE | 🟡 Watch | ⚠️ inferred. Services access across 118 sectors with MFN in 139 sub-sectors plus 5,000 professional visas is a real opening, but New Zealand is a small IT services wallet relative to the US and Europe | 2/5 |

## Foreign Investors Have Pulled ₹52,100 Crore Out of Indian Equities in October Alone

The flow data is now the dominant macro variable for Indian equities, and it got worse before it got better.

- **October outflow: about ₹52,100 crore** through October 16, already above the entire **₹35,861 crore** withdrawn in September, with two weeks of the month left.
- **Calendar 2026: more than ₹3.12 lakh crore** pulled from Indian equities.
- The **October 12-16 week** alone accounted for **₹7,934 crore** of settled selling.
- Foreign investors were net sellers for **15 consecutive sessions from September 24**, withdrawing roughly **₹84,000 crore** over that stretch, before turning marginal buyers of **₹1,166 crore on October 16**.

Finance Minister **Nirmala Sitharaman** put the cause on Monday in terms of global liquidity: easy money is what is allowing investors to exit Indian equities. The more orthodox explanation in the sell-side notes is the one the flows actually track — a US 10-year near **5.13%**, Brent above **$100**, and an Nifty 100 that has delivered about **1.2% annualised in dollar terms over five years**. The 2026 story is not a domestic earnings problem; the Nifty has repeatedly recovered on domestic institutional buying while foreigners sold.

That distinction decides which stocks the flow matters to. It is a valuation and ownership problem for the heavily foreign-owned large caps, and a volume and asset-gathering tailwind for the domestic intermediaries absorbing the other side.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| HDFCBANK, ICICIBANK, RELIANCE, INFY | 🟡 Watch | ⚠️ inferred. These are the highest-foreign-ownership index weights, so they absorb the marginal sell order; the offset is that domestic institutions have been buying the same names | 3/5 |
| HDFCAMC, NAM-INDIA | 🟢 Positive | ⚠️ inferred. Sustained domestic inflows are an AUM event for asset managers, and AUM is the revenue base; foreign selling does not reduce domestic SIP flow | 3/5 |
| CAMS, KFINTECH | 🟢 Positive | ⚠️ inferred. Registrar and transfer-agent revenue is a function of folio count and transaction volume, both of which rise when retail flow replaces foreign flow | 3/5 |
| BSE, ANGELONE, MOTILALOFS | 🟢 Positive | ⚠️ inferred. Higher domestic participation plus a record primary-market calendar is the volume and fee pool these three monetise | 3/5 |

## Jio Platforms' Anchor Book Was Subscribed More Than 30 Times

The largest IPO in Indian history cleared its first institutional test on Monday. **Jio Platforms' ₹30,213 crore issue** — a 100% fresh issue of up to 27 crore shares at a band of **₹1,065 to ₹1,119** — opened its **₹8,110 crore anchor tranche** and drew demand of **more than ₹2.5 lakh crore**, an oversubscription of over 30 times, with BlackRock, GIC, Norges Bank, SBI Mutual Fund and LIC among the marquee names.

The structure is what makes this issue different from the 2026 pattern: every rupee of proceeds accrues to the company, which intends to use it to prepay debt. That is deleveraging at the holdco, not a promoter exit.

- **Subscription window:** October 21 to 23; listing expected around **October 28**.
- **Implied valuation:** roughly **₹10.3 lakh crore** at the top of the band.
- **Anchor demand concentration:** a single ₹2.5 lakh crore bid pool for an ₹8,110 crore tranche is the clearest evidence yet that institutional appetite for Indian paper has not been damaged by the FPI exit — it has been redirected into primary issuance.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| BSE, ANGELONE, MOTILALOFS, IIFL | 🟢 Positive | ⚠️ inferred. A record issue with a 30x anchor book is listing-fee, brokerage and distribution revenue in a single week; the two OFS issues closing on Monday also cleared, which compounds the volume | 4/5 |
| CDSL, CAMS, KFINTECH | 🟢 Positive | ⚠️ inferred. A retail-heavy anchor and subscription cycle adds demat accounts and folios that persist after listing | 3/5 |
| RELIANCE | 🟡 Watch | ⚠️ inferred. All proceeds go to Jio Platforms to repay debt, so the holdco benefit is a lower consolidated leverage ratio rather than cash; the value unlock argument is real but it is already in the price of a ₹10.3 lakh crore mark | 3/5 |

## The Close: PSU Banks the Only Green Sector as Private Banks Broke the Index

The two-day rally ended hard. The **Sensex fell 876.37 points, or 1.17%, to 73,852.90** and the **Nifty 50 fell 257.20 points, or 1.11%, to 22,888.95**, closing below 22,900. The **Bank Nifty lost 0.64% to 55,488.10**, and the India VIX rose about 6% to **14.93**.

- **Nifty PSU Bank was the only sectoral index in the green, up 2.28%.** Union Bank rose 5.09% on a 30% year-on-year profit increase, PNB 4.82%, Federal Bank 3.92%, Canara Bank 3.10% and Bank of Baroda 2.95%. Karur Vysya Bank touched a lifetime high.
- **Private banks were the drag: Nifty Private Bank fell 1.89%.** Axis Bank dropped **4.19%** despite a 39.4% rise in consolidated net profit, and HDFC Bank fell nearly 3% despite a 4.7% increase in net profit. This was a valuation and expectations reset, not an earnings miss.
- **Nifty IT fell 1.56%**, with Infosys down 2.63% after Friday's 4.9% gain.
- **Gainers:** JSW Steel 2.06%, ONGC 1.35%, SBI 1.15%, Eicher Motors 1.48%, Adani Ports 0.89%, L&T 0.39%.
- **Losers:** Axis Bank, Tata Motors Passenger Vehicles 3.09%, Bajaj Finance, Trent, Infosys.
- **Earnings of the day:** UltraTech Cement's Q2 net profit rose 21.3% to ₹1,494 crore on 18.8% revenue growth, and the stock fell 2.4%; Hindustan Zinc roughly doubled quarterly profit on higher metal prices.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| Union Bank, PNB, Canara Bank, BoB, Federal Bank | 🟢 Positive | ✅ named. PSU banks delivered both the earnings and the price action, and they are the segment least exposed to foreign selling because foreign ownership is structurally low | 3/5 |
| AXISBANK, HDFCBANK, ICICIBANK, KOTAKBANK | 🟡 Watch | ✅ named. A 39.4% profit increase meeting a 4.19% fall is the market repricing the sector's multiple rather than its earnings; the signal is about expectations, not credit | 3/5 |
| JSWSTEEL, TATASTEEL | 🟢 Positive | ✅ named. JSW Steel led the index on a day when metals were the most resilient sector, and the New Zealand input relief lands on the same cost line | 2/5 |
| INFY, TECHM, HCLTECH, WIPRO | 🔴 Negative | ✅ named. IT has run about 9% in four sessions and gave back part of it on Monday; the sector is now trading the US demand cycle, not the rupee | 2/5 |